EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Asprosin‐FABP5 Interaction Modulates Mitochondrial Fatty Acid Oxidation through PPARα Contributing to MASLD Development

Yuan-Yuan Yu, Min Feng, Yi Chen, Hong-Lin Jia, Qi Zhang, Ming Tong, Yan-Xi Li, Yu Zhao, Xin-Xin Liu, Shi-Feng Cao, Zheng-Kai Wang, Hou-Wei Li und 2 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202415846 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Yuan-Yuan Yu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, SKLFZCD, (State Key Laboratory -Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardio…. Hauptthemen laut MEDLINE: Fatty Acid-Binding Proteins, PPAR alpha, Fatty Acids, Fibrillin-1. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alterations in liver metabolism play a pivotal role in the development and progression of metabolic dysfunction‐associated steatotic liver disease (MASLD). Asprosin is reported to be released from white adipose tissue during fasting and targets the liver. However, the role of asprosin, especially from organs other than adipose tissue, in MASLD remains poorly understood. These findings demonstrate that plasma asprosin levels are significantly elevated in MASLD patients and animal models. Additionally, asprosin expression increased in the liver of MASLD mice. Hepatocyte‐specific overexpression of asprosin impairs mitochondrial fatty acid β‐oxidation (FAO), whereas its knockdown not only enhances FAO in mice but also compensates for fenofibrate's limitations in MASLD treatment. Mechanistic investigations reveal that the interaction of asprosin with FABP5 facilitates its abnormal nuclear localization, and asprosin directly bound to and inhibites peroxisome proliferator‐activated receptor elements (PPREs), which negatively regulated PPARα transcriptional activity, and disrupts hepatic FAO pathways. GalNAc‐siRNAs targeting hepatic FABP5 ameliorate hepatic steatosis. These findings reveal that the secretory adipose factor asprosin is expected to act as a biological marker for early clinical diagnosis and prognostic evaluation of MASLD. Moreover, targeting hepatic asprosin gene inhibition and GalNAc‐siRNAs to inhibit hepatic FABP5 both offer potential therapeutic benefits in the treatment of MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty Acid-Binding ProteinsPPAR alphaFatty AcidsFibrillin-1Fatty LiverMitochondriaAnimalsMiceHumansOxidation-ReductionMaleDisease Models, AnimalMice, Inbred C57BLLiverNeoplasm ProteinsAdipokines

Stichwörter der Autor:innen

FABP5PPARαasprosinfenofibratehepatic steatosisinsulin resistancemitochondrial fatty acid β‐oxidation

Substanzen

Fatty Acid-Binding ProteinsPPAR alphaFatty AcidsFibrillin-1FABP5 protein, humanFBN1 protein, humanFabp5 protein, mouseNeoplasm ProteinsAdipokines

Autor:innen und Institutionen

  • Department of Pharmacology, SKLFZCD, (State Key Laboratory -Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin…
  • Department of Pathophysiology (Province Key Laboratory of Medicine-Food Homologous Resources and Prevention and Treatment of Metabolic Diseases), Basic Medical College, Qiqihar Medical University, Qiqihar, 161000, China.
  • Department of Cardiology at the Second Affiliated Hospital of Harbin Medical University, State Key Laboratory of Frigid Zone Cardiovascular Diseases, Harbin, 150086, China.
  • Department of Pharmacology, State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacy of The Second Affiliated Hospital, Harbin Medical University, Harbin, 150081, China.

ORCID-Profile: Yan Zhang

Förderung

  • National Natural Science Foundation of China
  • CAMS Innovation Fund for Medical Sciences

Zitieren

APA

Yu, Y. Y., Feng, M., Chen, Y., Jia, H. L., Zhang, Q., Tong, M., Li, Y. X., Zhao, Y., Liu, X. X., Cao, S. F., Wang, Z. K., Li, H. W., Liu, X., & Zhang, Y. (2025). Asprosin‐FABP5 Interaction Modulates Mitochondrial Fatty Acid Oxidation through PPARα Contributing to MASLD Development. Advanced Science. https://doi.org/10.1002/advs.202415846

Vancouver

Yu YY, Feng M, Chen Y, Jia HL, Zhang Q, Tong M, et al. Asprosin‐FABP5 Interaction Modulates Mitochondrial Fatty Acid Oxidation through PPARα Contributing to MASLD Development. Advanced Science. 2025. doi:10.1002/advs.202415846

BibTeX
@article{Yu2025,
  author = {Yu, Yuan-Yuan and Feng, Min and Chen, Yi and Jia, Hong-Lin and Zhang, Qi and Tong, Ming and Li, Yan-Xi and Zhao, Yu and Liu, Xin-Xin and Cao, Shi-Feng and Wang, Zheng-Kai and Li, Hou-Wei and Liu, Xue and Zhang, Yan},
  title = {Asprosin‐FABP5 Interaction Modulates Mitochondrial Fatty Acid Oxidation through PPARα Contributing to MASLD Development},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202415846}
}
Kostenlos starten →